Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
A Broad Look At Teva's Pipeline (NYSE:TEVA) | Seeking Alpha
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Active Biotech and Teva together in a Phase II clinical trial against Huntington's disease - Labiotech.eu
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Defining a role for laquinimod in multiple sclerosis - Bernd C. Kieseier, 2014
Molecules | Free Full-Text | Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Laquinimod - an overview | ScienceDirect Topics
FDA Marks Change in Clinical Test Dose of MS Therapy, Laquinimod
Teva Pharmaceuticals - Wikipedia
Laquinimod - Wikipedia
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Multiple Sclerosis Research: Will Teva and Biogen Come together for the sake of DMF, laquinimod polypill
EuroBiotech Report—Teva dumps laquinimod, Gilead-Galapagos, GV-Evox, Abivax data and ProQR | Fierce Biotech
Teva hit with largest-ever fine under US anti-corruption act - PMLiVE
AhR activators - friend or foe? - Hypha Discovery Blogs
AhR activators - friend or foe? - Hypha Discovery Blogs
Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS | Fierce Pharma
laquinimod
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
Laquinimod - an overview | ScienceDirect Topics
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Laquinimod | C19H17ClN2O3 | CID 54677946 - PubChem
